Drawing on the expertise of our founders and listening to the needs of the different voices within our ecosystem, we have developed a set of activities and initiatives to support collaboration, growth and investment.
We are continuously expanding and evolving our programme offering to provide deeper, more effective collaboration and to raise awareness globally of the region’s rich life sciences cluster.
Find out more about our current programmes below or contact us if you want more information.
Collaborate to Innovate
Collaborate to Innovate identifies SMEs with innovation or applied research needs and matches them to university research groups with complementary skills or expertise.Find out more
The Advanced Therapies Network (ATN) aims to support networking opportunities and knowledge exchange between academic organisations, life sciences companies and investors in this area.More about ATN
MedCity’s Angels is an initiative is growing a new community of angels focused specifically on life sciences to invest into innovative life sciences/healthcare businesses.
Digital health.London Accelerator
DigitalHealth.London is a collaborative programme delivered by MedCity, and London’s three Academic Health Science Networks – UCL Partners, Imperial College Health Partners and the Health Innovation Network.
It is supported by NHS England (London) and the Mayor’s Office. The DigitalHealth.London Accelerator is supported by the additional partner, CW+, and is part-funded through the European Regional Development Fund.Visit the website
Diagnostics Growth Hub
MedCity is convening a range of world-leading organisations to form the Diagnostics Growth Hub, a ‘one stop shop’ for diagnostics companies to be able to access all the support they need to flourish.
With Hub partners including Queen Mary University of London, King’s College London, Imperial College London, University College London, Asthma UK, The Doctors Laboratory and the London In-Vitro Diagnostics Cooperative, we can connect companies with the right expertise to support them on their journey to commercialisation.Find out more